These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 18295890

  • 1. Identification of a common HLA-A*0201-restricted epitope among SSX family members by mimicking altered peptide ligands strategy.
    He Y, Mao L, Lin Z, Deng Y, Tang Y, Jiang M, Li W, Jia Z, Wang J, Ni B, Wu Y.
    Mol Immunol; 2008 May; 45(9):2455-64. PubMed ID: 18295890
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.
    Ayyoub M, Rimoldi D, Guillaume P, Romero P, Cerottini JC, Valmori D, Speiser D.
    Cancer Res; 2003 Sep 01; 63(17):5601-6. PubMed ID: 14500401
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Identification of a novel HLA-A2-restricted cytotoxic T lymphocyte epitope from cancer-testis antigen PLAC1 in breast cancer.
    Liu W, Zhai M, Wu Z, Qi Y, Wu Y, Dai C, Sun M, Li L, Gao Y.
    Amino Acids; 2012 Jun 01; 42(6):2257-65. PubMed ID: 21710262
    [Abstract] [Full Text] [Related]

  • 7. Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.
    Terasawa H, Tsang KY, Gulley J, Arlen P, Schlom J.
    Clin Cancer Res; 2002 Jan 01; 8(1):41-53. PubMed ID: 11801539
    [Abstract] [Full Text] [Related]

  • 8. Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements.
    Huarte E, Sarobe P, Lu J, Casares N, Lasarte JJ, Dotor J, Ruiz M, Prieto J, Celis E, Borrás-Cuesta F.
    Clin Cancer Res; 2002 Jul 01; 8(7):2336-44. PubMed ID: 12114438
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of antitumor immunity efficacy of epitope-based vaccine with B16 cell line coexpressing HLA-A2/H-2kb and CTL multiepitope in HLA transgenic mice.
    Song S, Wang F, He X, He Y, Li D, Sun S.
    Vaccine; 2007 Jun 15; 25(25):4853-60. PubMed ID: 17418455
    [Abstract] [Full Text] [Related]

  • 10. Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4+ T cells.
    Valmori D, Qian F, Ayyoub M, Renner C, Merlo A, Gnjatic S, Stockert E, Driscoll D, Lele S, Old LJ, Odunsi K.
    Clin Cancer Res; 2006 Jan 15; 12(2):398-404. PubMed ID: 16428478
    [Abstract] [Full Text] [Related]

  • 11. Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses.
    Eguchi J, Hatano M, Nishimura F, Zhu X, Dusak JE, Sato H, Pollack IF, Storkus WJ, Okada H.
    Cancer Res; 2006 Jun 01; 66(11):5883-91. PubMed ID: 16740728
    [Abstract] [Full Text] [Related]

  • 12. Distinct but overlapping T helper epitopes in the 37-58 region of SSX-2.
    Ayyoub M, Merlo A, Hesdorffer CS, Speiser D, Rimoldi D, Cerottini JC, Ritter G, Chen YT, Old LJ, Stevanovic S, Valmori D.
    Clin Immunol; 2005 Jan 01; 114(1):70-8. PubMed ID: 15596411
    [Abstract] [Full Text] [Related]

  • 13. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.
    Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, Harao M, Inoue M, Tsunoda T, Nakatsuru S, Nakagawa H, Nakamura Y, Baba H, Nishimura Y.
    Clin Cancer Res; 2008 Oct 15; 14(20):6487-95. PubMed ID: 18927288
    [Abstract] [Full Text] [Related]

  • 14. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
    Komori H, Nakatsura T, Senju S, Yoshitake Y, Motomura Y, Ikuta Y, Fukuma D, Yokomine K, Harao M, Beppu T, Matsui M, Torigoe T, Sato N, Baba H, Nishimura Y.
    Clin Cancer Res; 2006 May 01; 12(9):2689-97. PubMed ID: 16675560
    [Abstract] [Full Text] [Related]

  • 15. An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR.
    Ayyoub M, Hesdorffer CS, Montes M, Merlo A, Speiser D, Rimoldi D, Cerottini JC, Ritter G, Scanlan M, Old LJ, Valmori D.
    J Clin Invest; 2004 Apr 01; 113(8):1225-33. PubMed ID: 15085202
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1.
    Ishizaki H, Tsunoda T, Wada S, Yamauchi M, Shibuya M, Tahara H.
    Clin Cancer Res; 2006 Oct 01; 12(19):5841-9. PubMed ID: 17020992
    [Abstract] [Full Text] [Related]

  • 17. Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma.
    Ayyoub M, Stevanovic S, Sahin U, Guillaume P, Servis C, Rimoldi D, Valmori D, Romero P, Cerottini JC, Rammensee HG, Pfreundschuh M, Speiser D, Lévy F.
    J Immunol; 2002 Feb 15; 168(4):1717-22. PubMed ID: 11823502
    [Abstract] [Full Text] [Related]

  • 18. Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes.
    Durántez M, López-Vázquez AB, de Cerio AL, Huarte E, Casares N, Prieto J, Borrás-Cuesta F, Lasarte JJ, Sarobe P.
    Scand J Immunol; 2009 Feb 15; 69(2):80-9. PubMed ID: 19144076
    [Abstract] [Full Text] [Related]

  • 19. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
    Machlenkin A, Paz A, Bar Haim E, Goldberger O, Finkel E, Tirosh B, Volovitz I, Vadai E, Lugassy G, Cytron S, Lemonnier F, Tzehoval E, Eisenbach L.
    Cancer Res; 2005 Jul 15; 65(14):6435-42. PubMed ID: 16024648
    [Abstract] [Full Text] [Related]

  • 20. The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides.
    Zhang XM, Zhang YF, Huang Y, Qu P, Ma B, Si SY, Li ZS, Li WX, Li X, Ge W, Hu PZ, Sui YF.
    Oncol Rep; 2008 Jul 15; 20(1):245-52. PubMed ID: 18575744
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.